Would be interested to hear opinions from people in terms of how this may affect us - good & bad.
Obviously IHL's mission is to address conditions that have unmet needs. If MindMed beat us to GAD with a treatment using LSD, how does that play out for our Psilocybin-assisted therapy?
The sector is certainly becoming legitimised and on one hand their news is positive for us as it gives hope that our treatment may head down the roads of approval, but at the same time, they are targeting the same addressable market as us.
Interested to hear discussion
IHL Price at posting:
44.0¢ Sentiment: Buy Disclosure: Held
